Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia

Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia

Anemia is a common and important complication in patients with chronic kidney disease (CKD). Accordingly, the current treatment is based on erythropoiesis stimulating agents (ESAs) and iron. Hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD) inhibitors (HIF-PHIs) have been developed to t...

Full description

Bibliographic Details
Main Authors: Xue Wang, Cuiting Wei, Delong Zhao, Xuefeng Sun, Fengge Zhu, Yan Mei, Qian Ma, Guangyan Cai, Xiangmei Chen, Ping Li
Format: Article
Language:English
Published: Karger Publishers 2023-08-01
Series:Kidney Diseases
Online Access:https://beta.karger.com/Article/FullText/533304

Internet

https://beta.karger.com/Article/FullText/533304

Similar Items